FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328010609> ?p ?o ?g. }

• W4328010609 endingPage "628" @default.
• W4328010609 startingPage "615" @default.
• W4328010609 abstract "Anaplastic lymphoma kinase (ALK) rearrangements are detected in 3-7% of advanced non-small cell lung cancer (NSCLC). There are currently 5 U.S Food and Drug Administration (FDA)-approved ALK tyrosine kinase inhibitors (TKIs) for the treatment of patients with ALK-positive lung cancer in the advanced/metastatic disease setting. Despite these advances, most patients with ALK-positive lung cancer who are treated with ALK TKI therapy ultimately experience disease progression due to various mechanisms of drug resistance. In this review, we discuss strategies to address acquired therapeutic resistance to ALK inhibition, novel agents and combinatorial strategies in development for both on and off-target resistance, and some emerging approaches to prolong response to ALK inhibitors.We performed a search of peer-reviewed literature in the English language, conference abstracts, and trial registrations from the MEDLINE (Ovid), Embase (Elsevier), and CENTRAL (Cochrane Library) databases and major international oncology meetings up to August 2022. We then screened for studies describing interventions to overcome ALK resistance based on review of each title and abstract.For patients with oligo-progression, treatment may include maintaining the same systemic treatment beyond progression while adding local therapies to progressing lesions. Strategies to combat ALK TKI resistance mediated by on-target resistance mechanisms include 4th generation TKIs (TPX-0131, NVL-655) and proteolysis-targeting chimeras (PROTACs) currently in development. While for those patients who develop tumor progression due to off-target (ALK independent) resistance, options may include combination therapies targeting ALK and other downstream or parallel pathways, novel antibody drug conjugates, or combinations of ALK inhibitors with chemotherapy and immunotherapy. Lastly, other potential strategies being explored in the clinic include circulating tumor DNA (ctDNA) surveillance to monitor for molecular mediators of drug resistance prior to frank progression on imaging studies and utilization of ALK TKIs in the adjuvant and neoadjuvant settings.Strategies to overcome resistance to currently available ALK inhibitors are urgently needed. Given the variety of resistance mechanisms, tailormade approaches are required for disease control." @default.
• W4328010609 created "2023-03-22" @default.
• W4328010609 creator A5074068244 @default.
• W4328010609 creator A5078137308 @default.
• W4328010609 date "2023-03-01" @default.
• W4328010609 modified "2023-10-05" @default.
• W4328010609 title "Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review" @default.
• W4328010609 cites W1903523058 @default.
• W4328010609 cites W1973843971 @default.
• W4328010609 cites W1973947576 @default.
• W4328010609 cites W1990487163 @default.
• W4328010609 cites W2000082608 @default.
• W4328010609 cites W2004202575 @default.
• W4328010609 cites W2030227571 @default.
• W4328010609 cites W2041835001 @default.
• W4328010609 cites W2048225862 @default.
• W4328010609 cites W2050249255 @default.
• W4328010609 cites W2055402151 @default.
• W4328010609 cites W2096744050 @default.
• W4328010609 cites W2106391833 @default.
• W4328010609 cites W2107211259 @default.
• W4328010609 cites W2113327188 @default.
• W4328010609 cites W2134787029 @default.
• W4328010609 cites W2139110945 @default.
• W4328010609 cites W2139483106 @default.
• W4328010609 cites W2147038864 @default.
• W4328010609 cites W2159587676 @default.
• W4328010609 cites W2170144893 @default.
• W4328010609 cites W2172208023 @default.
• W4328010609 cites W2272802268 @default.
• W4328010609 cites W2366619518 @default.
• W4328010609 cites W2400514548 @default.
• W4328010609 cites W2462487545 @default.
• W4328010609 cites W2482427906 @default.
• W4328010609 cites W2515048758 @default.
• W4328010609 cites W2516929867 @default.
• W4328010609 cites W2536769127 @default.
• W4328010609 cites W2581996620 @default.
• W4328010609 cites W2624310346 @default.
• W4328010609 cites W2738959174 @default.
• W4328010609 cites W2753065806 @default.
• W4328010609 cites W2789632821 @default.
• W4328010609 cites W2794623623 @default.
• W4328010609 cites W2797685139 @default.
• W4328010609 cites W2801986983 @default.
• W4328010609 cites W2803289473 @default.
• W4328010609 cites W2805354595 @default.
• W4328010609 cites W2883764978 @default.
• W4328010609 cites W2890314056 @default.
• W4328010609 cites W2890523839 @default.
• W4328010609 cites W2893495711 @default.
• W4328010609 cites W2894476389 @default.
• W4328010609 cites W2896538952 @default.
• W4328010609 cites W2969431490 @default.
• W4328010609 cites W2978074062 @default.
• W4328010609 cites W2982269583 @default.
• W4328010609 cites W2996630100 @default.
• W4328010609 cites W3003963326 @default.
• W4328010609 cites W3007665819 @default.
• W4328010609 cites W3008159666 @default.
• W4328010609 cites W3087210493 @default.
• W4328010609 cites W3088519161 @default.
• W4328010609 cites W3101089668 @default.
• W4328010609 cites W3147820834 @default.
• W4328010609 cites W3172667188 @default.
• W4328010609 cites W3173160576 @default.
• W4328010609 cites W3176833090 @default.
• W4328010609 cites W3186488369 @default.
• W4328010609 cites W3189724491 @default.
• W4328010609 cites W3196750844 @default.
• W4328010609 cites W3201219318 @default.
• W4328010609 cites W4200404814 @default.
• W4328010609 cites W4200432068 @default.
• W4328010609 cites W4205379795 @default.
• W4328010609 cites W4281289792 @default.
• W4328010609 cites W4283168725 @default.
• W4328010609 doi "https://doi.org/10.21037/tlcr-22-708" @default.
• W4328010609 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37057106" @default.
• W4328010609 hasPublicationYear "2023" @default.
• W4328010609 type Work @default.
• W4328010609 citedByCount "3" @default.
• W4328010609 countsByYear W43280106092023 @default.
• W4328010609 crossrefType "journal-article" @default.
• W4328010609 hasAuthorship W4328010609A5074068244 @default.
• W4328010609 hasAuthorship W4328010609A5078137308 @default.
• W4328010609 hasBestOaLocation W43280106091 @default.
• W4328010609 hasConcept C114851261 @default.
• W4328010609 hasConcept C117643217 @default.
• W4328010609 hasConcept C121608353 @default.
• W4328010609 hasConcept C126322002 @default.
• W4328010609 hasConcept C143998085 @default.
• W4328010609 hasConcept C2776232967 @default.
• W4328010609 hasConcept C2776256026 @default.
• W4328010609 hasConcept C2779422266 @default.
• W4328010609 hasConcept C2779750558 @default.
• W4328010609 hasConcept C502942594 @default.
• W4328010609 hasConcept C71924100 @default.
• W4328010609 hasConcept C86803240 @default.

• next